Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
出版年份 2023 全文链接
标题
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
作者
关键词
-
出版物
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 37, Issue 5, Pages 101836
出版商
Elsevier BV
发表日期
2023-10-24
DOI
10.1016/j.beem.2023.101836
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
- (2023) Mercedes Mitjavila et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
- (2022) Guido Rindi et al. ENDOCRINE PATHOLOGY
- STREPTOZOTOCIN. 1982-2022: FORTY YEARS FROM THE FDA’S APPROVAL TO TREAT PANCREATIC NEUROENDOCRINE TUMORS
- (2022) Jaume Capdevila et al. NEUROENDOCRINOLOGY
- Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
- (2022) Sara Pusceddu et al. JAMA Network Open
- LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
- (2022) R. Salazar et al. ANNALS OF ONCOLOGY
- 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
- (2022) E. Baudin et al. ANNALS OF ONCOLOGY
- A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
- (2022) Pamela L. Kunz et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
- (2022) David L. Chan et al. BRITISH JOURNAL OF CANCER
- Treatment Outcomes of Well‐Differentiated High‐Grade Neuroendocrine Tumors
- (2021) Alex J. Liu et al. ONCOLOGIST
- Changing biological behaviour of NETs during the evolution of the disease: progress on progression
- (2021) Krystallenia I Alexandraki et al. ENDOCRINE-RELATED CANCER
- 568P FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors
- (2021) C. Lacombe et al. ANNALS OF ONCOLOGY
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- (2021) Sonya Youngju Park et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Manisha H. Shah et al. Journal of the National Comprehensive Cancer Network
- Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors (GTE)
- (2021) Paul Girot et al. NEUROENDOCRINOLOGY
- Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index
- (2021) H. Jeong et al. ESMO Open
- Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
- (2021) Marianne Pavel et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
- (2021) Taymeyah Al-Toubah et al. Journal of the National Comprehensive Cancer Network
- Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone
- (2021) Irene Virgolini LANCET ONCOLOGY
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- (2021) Jonathan R Strosberg et al. LANCET ONCOLOGY
- Chemotherapy in Neuroendocrine Tumors
- (2021) Satya Das et al. Cancers
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
- (2020) Jonathan Strosberg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Somatostatin Analogs in Clinical Practice: a Review
- (2020) Mariana Gomes-Porras et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Pavel et al. ANNALS OF ONCOLOGY
- The Role of Ki-67 Index Cut-off of 55% and Differentiation in Redefining NET and NEC for Grade 3 Gastrointestinal Neuroendocrine Neoplasms
- (2020) Huiying Shi et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Tumour Growth Rate to predict the outcome of patients with Neuroendocrine Tumours: Performance and sources of variability
- (2020) Clarisse Dromain et al. NEUROENDOCRINOLOGY
- Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide
- (2020) Taymeyah Al‐Toubah et al. ONCOLOGIST
- Management of carcinoid syndrome: a systematic review and meta-analysis
- (2019) Johannes Hofland et al. ENDOCRINE-RELATED CANCER
- Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
- (2019) Juan W Valle et al. Future Oncology
- Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
- (2019) Kosmas Daskalakis et al. Endocrine Connections
- Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
- (2019) Angela Lamarca et al. CLINICAL CANCER RESEARCH
- High-grade progression confers poor survival in pancreatic neuroendocrine tumors
- (2019) Johan Botling et al. NEUROENDOCRINOLOGY
- Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms
- (2018) Timon Vandamme et al. ENDOCRINE-RELATED CANCER
- Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
- (2018) Lingaku Lee et al. EXPERT OPINION ON PHARMACOTHERAPY
- Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
- (2018) Esben Andreas Carlsen et al. ENDOCRINE-RELATED CANCER
- Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
- (2017) Anna Angelousi et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
- (2017) Anders Sundin et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
- (2017) Roberto Buzzoni et al. OncoTargets and Therapy
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study
- (2016) Philippe Ruszniewski et al. DIGESTIVE AND LIVER DISEASE
- EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
- (2016) Aaron I. Vinik et al. Endocrine Practice
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
- (2016) Martyn E Caplin et al. ENDOCRINE-RELATED CANCER
- Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.
- (2016) Simron Singh et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
- (2016) M. Falconi et al. NEUROENDOCRINOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
- (2016) Anja Rinke et al. NEUROENDOCRINOLOGY
- Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
- (2015) S. Van Binnebeek et al. EUROPEAN RADIOLOGY
- Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
- (2015) Catherine Lombard-Bohas et al. PANCREAS
- Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial
- (2014) Emmanuel Mitry et al. EUROPEAN JOURNAL OF CANCER
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia
- (2013) Valérie Bernard et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues
- (2011) H.-B. Fiebrich et al. ONCOLOGIST
- Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
- (2010) Martin B Niederle et al. ENDOCRINE-RELATED CANCER
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now